slrn-20241209

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

_____________________

FORM 8-K

_____________________

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 9, 2024

_____________________

ACELYRIN, INC.

(Exact name of registrant as specified in its charter)

_____________________

Delaware

001-41696

85-2406735

(State or other jurisdiction
of incorporation)

(Commission
File Number)

(IRS Employer
Identification No.)

4149 Liberty Canyon Road

91301

Agoura Hills, California

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (805) 730-0360

N/A

(Former name or former address, if changed since last report.)

_____________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.00001 par value per share

SLRN

Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company x

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On December 9, 2024, Gil M. Labrucherie, the Chief Financial Officer and Chief Business Officer of ACELYRIN, INC. (the “Company”), notified the Company of his intention to resign from the Company, effective January 2, 2025, to pursue an external opportunity.

In connection therewith, the Company has entered into a Transition and Consulting Agreement with Mr. Labrucherie (the “Transition Agreement”), pursuant to which Mr. Labrucherie will provide consulting services to the Company from January 3, 2025 through March 31, 2025 at an hourly rate of $500. The Transition Agreement provides for the continued vesting of Mr. Labrucherie’s outstanding equity awards through March 31, 2025.

The foregoing description of the Transition Agreement does not purport to be complete and is subject to, and qualified in its entirety by reference to, the full text of the Transition Agreement which is filed as Exhibit 10.1 hereto and is incorporated by reference.

Item 8.01 Other Events.

On December 10, 2024, the Company issued a press release announcing the top-line results from the Phase 2b/3 trial of izokibep, an investigational treatment for non-infectious non-anterior uveitis. A copy of the Company’s press release, titled “ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis” is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.


Exhibit No.						Description



10.1						Transition and Consulting Agreement between the Company an d Gil M. Labrucherie
99.1						ACELYRIN, Inc. Press Release dated December 10, 2024
104						Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	ACELYRIN, INC.

Dated: December 10, 2024	By:	/s/ Amar Murugan
		Amar Murugan
		Chief Legal Officer

ACELYRIN INC. filed SEC Form 8-K: Financial Statements and Exhibits